AI assistant
Sending…
Immunovant, Inc. — Director's Dealing 2023
Apr 19, 2023
31436_dirs_2023-04-19_c1f6ddd0-b621-499d-ac67-141481fedd22.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2023-04-17
Reporting Person: Stout Jay S (Chief Technology Officer)
More from Immunovant, Inc.
Annual Report
2026
May 20
Regulatory Filings
2026
May 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Feb 27
Earnings Release
2026
Feb 6
Interim / Quarterly Report
2026
Feb 6
Director's Dealing
2026
Jan 23
Director's Dealing
2026
Jan 9
Director's Dealing
2025
Dec 19
Capital/Financing Update
2025
Dec 12